Regarding the use and efficacy of maintenance therapy with FLT3 inhibitors, a recent publication reported the results of the European Group for Blood and Marrow Transplantation (EBMT) registry-based study, which included 462 patients with FLT3 mutated AML. Here, FLT3 is linked to acute myeloid leukemia.